modelR03BB07

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:UmeclidiniumBromide
ATC code:R03BB07
route:inhalation
compartments:2
dosage:125mg
volume of distribution:86L
clearance:151L/h
other parameters in model implementation

Umeclidinium bromide is a long-acting muscarinic antagonist (LAMA) used as a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is administered as an inhalation powder and is approved for use in adults to improve airflow and reduce symptoms in COPD patients.

Pharmacokinetics

Reported PK parameters in healthy adult subjects following inhaled administration of umeclidinium bromide.

References

  1. Mehta, R, et al., & Lipson, DA (2020). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Clinical pharmacokinetics 59(1) 67–79. DOI:10.1007/s40262-019-00794-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/31321713

  2. Yang, S, et al., & Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical pharmacokinetics 60(7) 887–896. DOI:10.1007/s40262-021-00988-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33598874

  3. Church, A, et al., & Shah, P (2014). Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC pulmonary medicine 14 2–None. DOI:10.1186/1471-2466-14-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24393134

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)